ES2103305T3 - Produccion de inhibidor de interleuquina-1 humana recombinada. - Google Patents

Produccion de inhibidor de interleuquina-1 humana recombinada.

Info

Publication number
ES2103305T3
ES2103305T3 ES91900515T ES91900515T ES2103305T3 ES 2103305 T3 ES2103305 T3 ES 2103305T3 ES 91900515 T ES91900515 T ES 91900515T ES 91900515 T ES91900515 T ES 91900515T ES 2103305 T3 ES2103305 T3 ES 2103305T3
Authority
ES
Spain
Prior art keywords
human interleukin
recombined human
inhibitor production
inhibitor
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91900515T
Other languages
English (en)
Inventor
Robert Hageman
Stephen P Eisenberg
David Dripps
Ronald Evans
Henryk Cudny
Robert C Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Boulder Inc
Original Assignee
Amgen Boulder Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Boulder Inc filed Critical Amgen Boulder Inc
Application granted granted Critical
Publication of ES2103305T3 publication Critical patent/ES2103305T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE DESCUBRIO UN METODO PARA LA PRODUCCION DE CANTIDADES COMERCIALES DEL INHIBIDOR DE INTERLEUCINA-1 (IL-LI) ALTAMENTE PURIFICADO DESDE UN HUESPED RECOMBINANTE. TAMBIEN SE DESCUBRIO UN HUESPED E.COLI RECOMBINANTE PREFERENTE PARA UTILIZAR EN ESTE METODO.
ES91900515T 1989-11-29 1990-11-29 Produccion de inhibidor de interleuquina-1 humana recombinada. Expired - Lifetime ES2103305T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44265289A 1989-11-29 1989-11-29

Publications (1)

Publication Number Publication Date
ES2103305T3 true ES2103305T3 (es) 1997-09-16

Family

ID=23757611

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91900515T Expired - Lifetime ES2103305T3 (es) 1989-11-29 1990-11-29 Produccion de inhibidor de interleuquina-1 humana recombinada.

Country Status (17)

Country Link
US (1) US5453490A (es)
EP (1) EP0502956B1 (es)
JP (1) JP3014007B2 (es)
KR (1) KR0182819B1 (es)
AT (1) ATE152172T1 (es)
AU (1) AU651955B2 (es)
BR (1) BR9007883A (es)
CA (1) CA2068320C (es)
DE (1) DE69030582T2 (es)
DK (1) DK0502956T3 (es)
ES (1) ES2103305T3 (es)
FI (1) FI104733B (es)
GR (1) GR3024031T3 (es)
HK (1) HK1006856A1 (es)
HU (1) HUT64582A (es)
NO (1) NO305290B1 (es)
WO (1) WO1991008285A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5861476A (en) * 1994-02-02 1999-01-19 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5880096A (en) * 1994-02-02 1999-03-09 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5786331A (en) * 1994-02-02 1998-07-28 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5608035A (en) * 1994-02-02 1997-03-04 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
IT1270662B (it) * 1994-10-13 1997-05-07 Applied Research Systems Antagonista della interleuchina-1
US5837495A (en) * 1994-10-13 1998-11-17 Applied Research Systems Ars Holding N.V. DNA encoding interleukin-1 antagonist
US5981713A (en) * 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
ES2615357T3 (es) * 1996-12-06 2017-06-06 Amgen Inc. Terapia de combinación usando un inhibidor de IL-1 para tratar enfermedades mediadas por IL-1
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
KR20040023630A (ko) 2001-06-26 2004-03-18 아브게닉스, 인크. Ｏｐｇｌ에 결합하는 항체
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
NZ593428A (en) 2002-09-06 2013-01-25 Amgen Inc Therapeutic human anti-il-1r1 monoclonal antibody
DK1729810T3 (en) 2004-04-02 2018-12-03 Swedish Orphan Biovitrum Ab Publ PROCEDURE FOR REDUCING AGGREGATION OF IL-1RA
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
US20070248653A1 (en) * 2006-04-20 2007-10-25 Cochrum Kent C Hemostatic compositions and methods for controlling bleeding
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
WO2009025763A2 (en) * 2007-08-16 2009-02-26 Schepens Eye Research Institute Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
WO2009062339A1 (en) 2007-11-14 2009-05-22 General Regeneratives, Ltd. Methods of using interleukin-1 receptor antagonist as a myeloprotective agent
US10106587B2 (en) 2008-02-27 2018-10-23 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
CN101690801B (zh) 2009-10-26 2012-08-01 上海交通大学 白细胞介素-1受体拮抗剂的用途及其药物组合物
PL3470421T3 (pl) 2010-07-29 2023-10-23 Buzzard Pharmaceuticals AB Chimeryczne antagonisty receptora il-1 typu i
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
RU2014107743A (ru) * 2011-07-29 2015-09-10 Илэвэн Байотерапьютикс, Инк. Очищенные белки
CN112142855A (zh) 2012-05-18 2020-12-29 爱德迪安（北京）生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
JP6450364B2 (ja) 2013-03-13 2019-01-09 セセン バイオ， インコーポレイテッド 眼送達のためのキメラサイトカイン製剤
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US9758806B2 (en) * 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
WO2015067791A1 (en) 2013-11-11 2015-05-14 Ascendis Pharma Relaxin Division A/S Relaxin prodrugs
US9833474B2 (en) 2013-11-26 2017-12-05 Biomet Biologies, LLC Methods of mediating macrophage phenotypes
US20160000936A1 (en) 2014-06-10 2016-01-07 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
WO2018022982A1 (en) 2016-07-29 2018-02-01 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
US11285196B2 (en) 2017-03-13 2022-03-29 Eslam Abbas Baseuny Multivalent biologic constructs for inducing a therapeutic modulation of cellular response and uses thereof
EP3836954A1 (en) 2018-08-13 2021-06-23 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3855747T2 (de) * 1987-08-26 1997-06-12 Biogen Inc Biologische materialien, deren herstellung und verwendung in der therapie
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
KR0148009B1 (ko) * 1988-05-27 1998-08-01 그래고리 비. 아보트 인터루킨-1 억제제
WO1991017184A1 (en) * 1990-04-27 1991-11-14 The Upjohn Company Modified interleukin-1 inhibitors
AU655766B2 (en) * 1990-05-01 1995-01-12 Chiron Corporation Interleukin-1 antagonist and uses thereof

Also Published As

Publication number Publication date
ATE152172T1 (de) 1997-05-15
AU651955B2 (en) 1994-08-11
HU9201777D0 (en) 1992-12-28
EP0502956B1 (en) 1997-04-23
KR920703792A (ko) 1992-12-18
NO922138L (no) 1992-05-29
JPH05503007A (ja) 1993-05-27
DE69030582T2 (de) 1998-06-25
NO305290B1 (no) 1999-05-03
HK1006856A1 (en) 1999-03-19
CA2068320C (en) 2000-10-17
FI922434A0 (fi) 1992-05-27
AU6900791A (en) 1991-06-26
NO922138D0 (no) 1992-05-29
DK0502956T3 (da) 1997-10-20
US5453490A (en) 1995-09-26
EP0502956A4 (en) 1992-12-09
FI922434A (fi) 1992-05-27
DE69030582D1 (de) 1997-05-28
EP0502956A1 (en) 1992-09-16
BR9007883A (pt) 1992-09-29
CA2068320A1 (en) 1991-05-30
JP3014007B2 (ja) 2000-02-28
HUT64582A (en) 1994-01-28
KR0182819B1 (en) 1999-04-01
FI104733B (fi) 2000-03-31
WO1991008285A1 (en) 1991-06-13
GR3024031T3 (en) 1997-10-31

Similar Documents

Publication Publication Date Title
ES2103305T3 (es) Produccion de inhibidor de interleuquina-1 humana recombinada.
ITMI920569A0 (it) Procedimento per la fabbricazione di tastiere
IT1182721B (it) Procedimento di purificazione di proteine ossee
IT1142464B (it) Procedimento per il frazionamento di soluzioni di misugli proteici
IT8620860A0 (it) Procedimento per l'esercizio di un estrusore.
FI894671A (fi) Reglerbar faestanordning.
DE3769523D1 (de) Schraubenkompressor.
ITMI912196A0 (it) Procedimento per la produzione di ossidi olefinici
ATE38036T1 (de) Benzothiophenderivate als bronchodilatoren.
KR950702242A (ko) 사포린 함유 단백질의 재조합 생산방법(Recombinant production of saporin-containing proteins)
IT8519040A0 (it) Cloni di cdna di eritropietina umana.
DK377787D0 (da) Interferonfragmenter
IT8522977A0 (it) Purificiazione di l-fenilalanina.
IT8248055A0 (it) Procedimento per la produzione di ditiazolil-2(2.2')-disolfuri
IT8622149A0 (it) Procedimento per la produzione di gnocchi.
IT9020860A0 (it) Procedimento per la depurazione fine di gas
IT8322407V0 (it) Lamella per crivelli di mietitrebbiatrici.
IT8920903A0 (it) Procedimento per la produzione di coke.
IT1231506B (it) Procedimento per la purificazione di polieteri polioli.
AU2885689A (en) Novel proteins derived from human alpha2-plasmin inhibitor orproteins similar thereto
IT1233109B (it) Servo-meccanismo per regolatori di pressione di gas
IT8423757A1 (it) Procedimento per la fabbricazione di poltacetilene
IT8819919A0 (it) Procedimento perfezionato per laproduzione di componenti ceramici.
IT1174139B (it) Procentimento per la fabbricazione di magnesia refrattaria
IT8419249A0 (it) Procedimento per la sintesi di o-isopropossifenolo.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 502956

Country of ref document: ES